A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

Also called NCT04531462

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 129 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04531462
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04531462. Randomized; quadruple masking; primary purpose treatment. Start 2020-10-05 (actual); primary completion 2022-08-19 (actual). Results posted on 2024-03-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct04531462
Content hash
98c6da17093428fa168eaad3c9ae4965ae342f7e18507e1db91c09837ac0a0f7